Skip to content
AnalystLens

DEXCOM INC 8-K Report, Financial Results (Apr 25, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed April 25, 2024
Period End
April 25, 2024
Security
DXCM
In the record · 2016–202610-K1110-Q328-K134

DXCM filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed April 25, 2024. Cited figures are marked; the original filing is the authoritative source.

DexCom reported first-quarter 2024 revenue of $921.0 milliona, up 24% year-over-year on a reported basis and 25% on an organic basis, driven mainly by CGM volume growth and new customer additions.

Sensor and other revenue rose 31% to $854.3 millionb, while hardware revenue fell 26% to $66.7 million. GAAP operating income was $101.1 million (11.0% of revenue), up 460 basis points from the prior year, and non-GAAP operating income was $140.2 million (15.2%). Gross margin moved lower: GAAP gross margin was 61.0% versus 62.4% a year earlier, and non-GAAP gross margin was 61.8% versus 63.4%.

GAAP net income of $146.4 millionc ($0.36 per diluted share) was flattered by a $13.9 million income tax benefit, and non-GAAP net income of $128.2 million ($0.32 per diluted share) reflects a $57.3 million tax adjustment, primarily tied to the tax effect of the Verily milestone payment. Investors should weigh the operating line more heavily than the bottom line this quarter. Adjusted EBITDA was $220.9 million.

The company ended the quarter with $2.90 billiond in cash, cash equivalents and marketable securities, and its revolving credit facility remains undrawn. For fiscal 2024, DexCom updated revenue guidance to approximately $4.20 to $4.35 billion (17% to 21% organic growth) and reiterated its non-GAAP gross margin (63% to 64%), non-GAAP operating margin (about 20%) and Adjusted EBITDA margin (about 29%) outlook. The filing does not state the prior revenue range, so the direction of the revision cannot be determined from this document alone.

02—Key points

Key Highlights

  1. Revenue of $921.0M, up 24% reported and 25% organic year-over-year; U.S. and international each grew 24% on a reported basis.
  2. Sensor and other revenue rose 31% to $854.3M (93% of revenue), while hardware revenue declined 26% to $66.7M.
  3. GAAP operating income of $101.1M (11.0% margin) rose 460 bps year-over-year; non-GAAP operating income was $140.2M (15.2%).
  4. Gross margin contracted: GAAP 61.0% vs. 62.4% and non-GAAP 61.8% vs. 63.4% a year earlier.
  5. GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.32 were boosted by tax items, including a $13.9M GAAP tax benefit and $57.3M of non-GAAP tax adjustments.
  6. FY2024 revenue guidance updated to $4.20 to $4.35 billion; non-GAAP gross margin, operating margin and Adjusted EBITDA margin guidance reiterated.
  7. Cash, equivalents and marketable securities of $2.90B with an undrawn revolving credit facility; FDA clearance obtained for Stelo, a CGM for type 2 patients not on insulin, sold without a prescription.

03—Questions

Frequently Asked Questions

  1. How did DexCom perform on revenue and profitability in Q1 2024?

    Revenue grew 24% reported (25% organic) to $921.0 million, led by sensor growth of 31%. GAAP operating income was $101.1 million, up from $47.2 million a year earlier, and non-GAAP operating income was $140.2 million, up from $78.6 million. Operating margin expansion was strong, even though gross margin declined.

  2. Did DexCom change its 2024 outlook?

    Yes, for revenue. Guidance was updated to approximately $4.20 to $4.35 billion, implying 17% to 21% organic growth. Non-GAAP gross margin (63% to 64%), non-GAAP operating margin (about 20%) and Adjusted EBITDA margin (about 29%) guidance was reiterated. The filing does not provide the prior revenue range, so the size of the change is not determinable here.

  3. Why does GAAP net income look strong relative to operating income?

    GAAP net income of $146.4 million exceeded GAAP operating income of $101.1 million because of $31.4 million of other income (largely interest income on cash and investments) and a $13.9 million income tax benefit. The tax benefit is non-recurring in nature and inflates the quarter's earnings per share relative to operating performance.

  4. Is DexCom's balance sheet in a position to fund growth?

    The balance sheet shows $2.90 billion in cash, cash equivalents and marketable securities as of March 31, 2024, with the revolving credit facility undrawn. Management cites this liquidity as supporting expanded production capacity and new market opportunities. Long-term senior convertible notes totaled $2.44 billion, which is the main debt obligation.

  5. What are the main drivers and risks highlighted in this quarter's results?

    Growth is driven by CGM volume and new customer additions as real-time CGM awareness rises. Risks flagged in the filing include the decline in hardware revenue (down 26%), lower gross margin, and ongoing intellectual property litigation costs of $25.2 million in the quarter related to the Abbott patent case. Forward-looking statements are subject to risks described in DexCom's Form 10-K and 10-Q filings.

04—Continue

← View all 8-K filings